Notably, the phase III KEYNOTE-189 trial reported that pembrolizumab combined with pemetrexed and platinum-based chemotherapy substantially increased PFS and OS in previously untreated patients with metastatic non-squamous NSCLC lacking EGFR or ALK mutations [11]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.